Adhera Therapeutics (MRNA):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Adhera Therapeutics (MRNA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C9908
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:58
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Adhera Therapeutics (Adhera) is a nucleic acid-based drug discovery and development company that focuses on rare diseases. It focuses on treating the intersection of arthritis, hypertension, pain, and cancer using combination therapies of already approved drugs. The company is developing and commercializing late stage, non-addictive pain therapeutics. Based on its drug discovery platform, SMARTICLES Adhera develops proprietary single and double-stranded nucleic acid therapeutics including microRNA mimics, siRNAs, antagomirs and antisense compounds envisioned to activate various RNA-based mechanisms of action. The company is developing CEQ508 in Phase I clinical studies for treating patients with familial adenomatous polyposis (FAP). Adhera is headquartered in City of Industry, California, the US.

Adhera Therapeutics (MRNA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Adhera Therapeutics, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Marina Biotech Acquires Prestalia from Symplmed Pharma 12
Marina Biotech to Acquire Intranasal Ketamine Program from Turing Pharma 13
Venture Financing 14
Marina Biotech Raises USD0.3 Million in Financing Round 14
Partnerships 15
Rosetta Genomics And Marina Biotech Enter Into Agreement To Develop MicroRNA Diagnostics 15
Marina Biotech Enters Into Co-Development Agreement With Girindus 17
Merger 18
Marina Biotech and IthenaPharma Merges 18
Licensing Agreements 19
Marina Biotech Enters into Development and Licensing Agreement with Autotelic 19
Oncotelic Enters into Licensing Agreement with Marina Biotech 20
LipoMedics Enters into Licensing Agreement Marina Biotech for SMARTICLES 21
Autotelic Enters into Licensing Agreement with Marina Biotech 22
Marina Biotech Enters into Licensing Agreement with Autotelic 23
Marina Biotech Enters into Licensing Agreement for NOV582 24
Marina Biotech Exercises Option for Licensing Agreement for Smarticles and DiLA2 Platform 25
Hongene Biotech Enters into Licensing Agreement with Marina Biotech 26
Marina Biotech Enters into Licensing Agreement with MiNA Therapeutics 27
Marina Biotech Amends Licensing Agreement with Mirna Therapeutics for MicroRNA Therapeutics 28
Arcturus Therapeutics Enters Into Licensing Agreement With Marina Biotech For Unlocked Nucleobase Analog Technology 30
Marina Biotech Enters Into Licensing Agreement With Tekmira Pharma For RNAi Technology 31
Marina Biotech Enters Into Licensing Agreement With Novartis For CRN Technology 32
Marina Biotech Enters Into Licensing Agreement With ProNAi Therapeutics For DNAi Therapeutics 33
Equity Offering 34
Marina Biotech Raises USD11.7 Million in Private Placement 34
Marina Biotech Raises USD0.3 Million in Private Placement of Shares 35
Marina Biotech Raises USD1 Million in Private Placement of Preferred Stock and Warrants 36
Marina Biotech Raises USD6 Million in Private Placement Of Shares 37
Marina Biotech Raises USD1.2 Million in Private Placement of Shares and Warrants 38
Marina Biotech Completes Private Placement Of Shares For US$2 Million 39
Marina Biotech Completes Private Placement Of Redeemable Preferred Stock For US$5 Million 40
Debt Offering 41
Marina Biotech to Raise USD0.5 Million in Private Placement of Notes Due 2018 41
Marina Biotech Raises USD0.2 Million in Private Placement of 5% Notes Due 2018 42
Marina Biotech Raises USD0.1 Million in Issue of Convertible Promissory Notes 43
Asset Transactions 44
Marina Biotech to Sell DiLA2 Delivery Platform for USD1.5 Million 44
Adhera Therapeutics – Key Competitors 45
Adhera Therapeutics – Key Employees 46
Adhera Therapeutics – Locations And Subsidiaries 47
Head Office 47
Other Locations & Subsidiaries 47
Recent Developments 48
Corporate Communications 48
Aug 06, 2018: Marina Biotech appoints Jay D. Schwartz to serve as senior vice president, commercial operations 48
Jun 29, 2018: Marina Biotech Names Uli Hacksell And Robert C. Moscato As Board Directors 49
Jun 20, 2018: Marina Biotech Appoints Robert Moscato to Chief Executive Officer 50
Jul 05, 2017: Marina Biotech Announces the Appointment of Dr. Vuong Trieu as Executive Chairman 51
Jun 26, 2017: Marina Biotech appoints chief commercial officer 52
Feb 21, 2017: Marina Biotech Appoints Dr. Seymour Fein as Chief Medical Officer 53
Feb 14, 2017: Marina Biotech Announces Key Additions to its Executive Management Team 54
Product News 55
03/13/2017: Marina Biotech to Present A Late Breaking Poster on the Safety and Tolerability of CEQ508 for FAP at the Society of Toxicology 56th Annual Meeting on March 16 55
Other Significant Developments 56
Apr 05, 2017: Marina Biotech Provides Business Update 56
Appendix 58
Methodology 58
About GlobalData 58
Contact Us 58
Disclaimer 58

List of Tables
Adhera Therapeutics, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Adhera Therapeutics, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Adhera Therapeutics, Deals By Therapy Area, 2012 to YTD 2018 9
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Marina Biotech Acquires Prestalia from Symplmed Pharma 12
Marina Biotech to Acquire Intranasal Ketamine Program from Turing Pharma 13
Marina Biotech Raises USD0.3 Million in Financing Round 14
Rosetta Genomics And Marina Biotech Enter Into Agreement To Develop MicroRNA Diagnostics 15
Marina Biotech Enters Into Co-Development Agreement With Girindus 17
Marina Biotech and IthenaPharma Merges 18
Marina Biotech Enters into Development and Licensing Agreement with Autotelic 19
Oncotelic Enters into Licensing Agreement with Marina Biotech 20
LipoMedics Enters into Licensing Agreement Marina Biotech for SMARTICLES 21
Autotelic Enters into Licensing Agreement with Marina Biotech 22
Marina Biotech Enters into Licensing Agreement with Autotelic 23
Marina Biotech Enters into Licensing Agreement for NOV582 24
Marina Biotech Exercises Option for Licensing Agreement for Smarticles and DiLA2 Platform 25
Hongene Biotech Enters into Licensing Agreement with Marina Biotech 26
Marina Biotech Enters into Licensing Agreement with MiNA Therapeutics 27
Marina Biotech Amends Licensing Agreement with Mirna Therapeutics for MicroRNA Therapeutics 28
Arcturus Therapeutics Enters Into Licensing Agreement With Marina Biotech For Unlocked Nucleobase Analog Technology 30
Marina Biotech Enters Into Licensing Agreement With Tekmira Pharma For RNAi Technology 31
Marina Biotech Enters Into Licensing Agreement With Novartis For CRN Technology 32
Marina Biotech Enters Into Licensing Agreement With ProNAi Therapeutics For DNAi Therapeutics 33
Marina Biotech Raises USD11.7 Million in Private Placement 34
Marina Biotech Raises USD0.3 Million in Private Placement of Shares 35
Marina Biotech Raises USD1 Million in Private Placement of Preferred Stock and Warrants 36
Marina Biotech Raises USD6 Million in Private Placement Of Shares 37
Marina Biotech Raises USD1.2 Million in Private Placement of Shares and Warrants 38
Marina Biotech Completes Private Placement Of Shares For US$2 Million 39
Marina Biotech Completes Private Placement Of Redeemable Preferred Stock For US$5 Million 40
Marina Biotech to Raise USD0.5 Million in Private Placement of Notes Due 2018 41
Marina Biotech Raises USD0.2 Million in Private Placement of 5% Notes Due 2018 42
Marina Biotech Raises USD0.1 Million in Issue of Convertible Promissory Notes 43
Marina Biotech to Sell DiLA2 Delivery Platform for USD1.5 Million 44
Adhera Therapeutics, Key Competitors 45
Adhera Therapeutics, Key Employees 46
Adhera Therapeutics, Subsidiaries 47

List of Figures
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Adhera Therapeutics, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

★海外企業調査レポート[Adhera Therapeutics (MRNA):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Neuland Laboratories Ltd (NEULANDLAB):製薬・医療:M&Aディール及び事業提携情報
    Summary Neuland Laboratories Ltd (Neuland Lab), a subsidiary of Neuland Health Sciences Pvt Ltd is an API manufacturing service provider that manufactures active pharmaceutical ingredients, advanced intermediates; and offers chemistry related services. The company provides APIs in various therapeuti …
  • Takeda Pharmaceutical Co Ltd (4502):企業の財務・戦略的SWOT分析
    Takeda Pharmaceutical Co Ltd (4502) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Global Marine Systems Ltd:電力:M&Aディール及び事業提携情報
    Summary Global Marine Systems Limited (Global Marine), a subsidiary of Bridgehouse Marine Limited, is a marine technology and engineering company. It provides submarine cable installation, maintenance and engineering services. Its capabilities include project management, subsea cable installation, s …
  • Bank Of Cyprus Public Company Ltd:企業の戦略・SWOT・財務分析
    Bank Of Cyprus Public Company Ltd - Strategy, SWOT and Corporate Finance Report Summary Bank Of Cyprus Public Company Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • LSIS Co Ltd (010120):企業の財務・戦略的SWOT分析
    LSIS Co Ltd (010120) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Adaptimmune Ltd-製薬・医療分野:企業M&A・提携分析
    Summary Adaptimmune Ltd (Adaptimmune), a subsidiary of Adaptimmune Therapeutics Plc is a clinical stage biotechnology company that develops T-cell therapy products for the treatment of cancer. The company’s pipeline peptides include NY-ESO TCR used to treat cancer cells, MAGE A-10 TCR used for the t …
  • Rabigh Refining & Petrochemical Co (2380):企業の財務・戦略的SWOT分析
    Rabigh Refining & Petrochemical Co (2380) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • Singapore Technologies Marine Ltd.:企業の戦略・SWOT・財務情報
    Singapore Technologies Marine Ltd. - Strategy, SWOT and Corporate Finance Report Summary Singapore Technologies Marine Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, p …
  • Capitol Federal Financial Inc:企業の戦略・SWOT・財務分析
    Capitol Federal Financial Inc - Strategy, SWOT and Corporate Finance Report Summary Capitol Federal Financial Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and …
  • E.ON SE (EOAN)-石油・ガス分野:企業M&A・提携分析
    Summary E.ON SE (E.ON), formerly E.ON AG, is an energy company that generates electricity, produces, stores, transports, and supplies gas and conducts trading, carbon sourcing, and electricity and gas distribution. It generates power from diverse fuel sources including wind, hydro, nuclear, coal, na …
  • International Consolidated Airlines Group, S.A.
    International Consolidated Airlines Group, S.A. - Strategy, SWOT and Corporate Finance Report Summary International Consolidated Airlines Group, S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, o …
  • Noor Takaful:企業の戦略・SWOT・財務情報
    Noor Takaful - Strategy, SWOT and Corporate Finance Report Summary Noor Takaful - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Evolution Mining Ltd:企業のM&A・事業提携・投資動向
    Evolution Mining Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Evolution Mining Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Hybrigenics SA (ALHYG):製薬・医療:M&Aディール及び事業提携情報
    Summary Hybrigenics SA (Hybrigenics) is a biopharmaceutical company that develops new targets and therapies against proliferative and non-cancerous diseases. Its lead product candidate Inecalcitol, is a vitamin D receptor agonist being assessed for various cancer indications including prostate cance …
  • Sinphar Pharmaceutical Co Ltd (1734):企業の財務・戦略的SWOT分析
    Sinphar Pharmaceutical Co Ltd (1734) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • MediPal Holdings Corp:企業の戦略・SWOT・財務情報
    MediPal Holdings Corp - Strategy, SWOT and Corporate Finance Report Summary MediPal Holdings Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Neoleukin Therapeutics Inc (NLTX):企業の財務・戦略的SWOT分析
    Summary Neoleukin Therapeutics Inc (Neoleukin), formely Aquinox Pharmaceuticals Inc is a biopharmaceutical company develops next generation immunotherapies to treat immunological disorders. The company's lead drug candidate NL-201 is a combined IL-2 and IL-15 protein therapeutic used as an agonist i …
  • Bilfinger Tebodin BV:企業の戦略的SWOT分析
    Bilfinger Tebodin BV - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • Axxam SpA-製薬・医療分野:企業M&A・提携分析
    Summary Axxam SpA (Axxam) is a partner research organization that provides drug discovery services. The organization offers drug discovery services such as molecular biology, assay development and reagent provision, compound management, hit characterization and profiling and electrophysiology, among …
  • Torrent Power Ltd (TORNTPOWER):企業の財務・戦略的SWOT分析
    Torrent Power Ltd (TORNTPOWER) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆